4-chloro-3-[1-ethyl-2-oxo-7-[2-(prop-2-enoylamino)phenyl]-1,6-naphthyridin-3-yl]-N-methoxybenzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-chloro-3-[1-ethyl-2-oxo-7-[2-(prop-2-enoylamino)phenyl]-1,6-naphthyridin-3-yl]-N-methoxybenzamide
• 化学式: C₂₇H₂₃ClN₄O₄
• 分子量: 502.957
• InChiKey: YBKGICXHTYHQAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
  申请人：Bifulco, JR. Neil

  公开号：US20150197519A1

  公开（公告）日：2015-07-16

  Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

  本处描述的是FGFR-4的抑制剂，包括含有此类化合物的药物组合物，以及使用此类化合物和组合物来抑制FGFR-4活性的方法。
• Inhibitors of the fibroblast growth factor receptor
  申请人：BLUEPRINT MEDICINES CORPORATION

  公开号：US10000490B2

  公开（公告）日：2018-06-19

  Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

  本文描述了 FGFR-4 的抑制剂、包括此类化合物的药物组合物以及使用此类化合物和组合物抑制 FGFR-4 活性的方法。
• US9695165B2
  申请人：——

  公开号：US9695165B2

  公开（公告）日：2017-07-04
• [EN] HETEROBICYCLIC COMPOUNDS AND THEIR USE AS FGFR4 RECEPTOR INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROBICYCLIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU RÉCEPTEUR FGFR4
  申请人：BLUEPRINT MEDICINES CORP

  公开号：WO2015108992A1

  公开（公告）日：2015-07-23

  Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof: Formula (I) wherein: (A) denotes a single or double bond; Warhead is a moiety capable of forming a covalent bond with a nucleophile; Ring A is a 5-8 membered aryl, 5-12 membered heteroaryl, 3-7 member monocyclic or bicyclic heterocyclyl; or 3-12 membered monocyclic or bicyclic cycloalkyl group; W is C or N, X and Z are each independently CH or N; Y is CH or N-R4 where R4 is H, C1-6alkyl, or 3-12 membered cycloalkyl; each of R1-R3 is, independently, halo, cyano, optionally substituted C1-6alkyl, optionally substituted C1-6alkoxy, hydroxy, oxo, amino, amido, alkyl urea, optionally substituted 3-7 member heterocyclyl; R7 is hydrogen or C1-6alkyl; or R7 together with Ring A forms a 8-12 membered bicyclic heterocyclyl optionally substituted with 1-5 occurrences of R1; m is 0-5; n is 0-5; and p is 0-2 as inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.